Navigation Links
Karolinska Development: EMEA Recommends Orphan Drug Designation for Acute Myeloid Leukemia Treatment
Date:2/18/2010

STOCKHOLM, February 18, 2010 /PRNewswire/ -- The European Medicines Agency (EMEA) recommends orphan drug status for Aprea's treatment of acute myeloid leukemia (AML). The treatment is currently undergoing a Phase I clinical study and a final decision from the European Commission regarding status is expected in a few weeks. Aprea is part of the Karolinska Development portfolio.

"Aprea is developing a new class of anticancer drugs for the treatment of acute myelogenous leukemia, the most common acute leukemia affecting adults which is currently lacking efficient treatment. An orphan drug status would significantly shorten the development time, lower development costs and, if approved, extend market exclusivity to the benefit of affected patients, Aprea and Karolinska Development," says Conny Bogentoft, CEO Karolinska Development.

Karolinska Development holds 43 percent of the Aprea share capital and votes. For further information about Aprea, please visit http://www.aprea.com.

About Karolinska Development

Karolinska Development manages one of the largest portfolios of life science companies in Europe.

Using a unique, highly cost-efficient business model, the management team guides the commercialization of world-class life science innovations, helping to shape the next-generation pharma industry. Since 2003, Karolinska Development has built a portfolio of some 40 companies; among the company's projects, 12 compounds are undergoing clinical trials. The portfolio also includes a total of 19 potential first-in-class products. http://www.karolinskadevelopment.com

    For more information, please contact:

    Conny Bogentoft, CEO Karolinska Development
    Tel: +46(0)706-88-61-43, e-mail:
    conny.bogentoft@karolinskadevelopment.com

SOURCE Karolinska Development AB


'/>"/>
SOURCE Karolinska Development AB
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Karolinska Development New Share Issue Completed - Raising 380 MSEK (36 MEUR)
2. Karolinska Development Portfolio Company Launches GMP Facility for Particulate Manufacturing
3. Karolinska Institutet to Test Vicals Vaxfectin(R) Adjuvant With Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
4. Karolinska Institute to Test Vicals Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
5. Video: The Looming Crisis in Cancer Drug Development: 97% of Adult Cancer Patients Do Not Take Advantage of Clinical Trial Programs
6. Data Monitoring Committee Recommends Continuation of Phase III Study of StemEx(R), a Cord Blood Stem Cell Product, for Leukemia and Lymphoma
7. Elbit Imaging Announces Data Monitoring Committee Recommends Continuation of Phase III Study of StemEx(R), a Cord Blood Stem Cell Product, for Leukemia and Lymphoma
8. Barclays Wealth Recommends Increasing Exposure to Laggard Sectors Including Consumer Staples, Pharmaceuticals and Telecoms
9. US Expert Panel Recommends the Use of Fractional Exhaled Nitric Oxide (FENO) in the Diagnosis and Management of Asthma
10. RiskMetrics Recommends Taro Shareholders Vote Against Taro Board of Directors
11. PROXY Governance Recommends Against Taros Board and Supports Sun
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016 Henry Schein, Inc. (Nasdaq: ... care products and services to office-based dental, animal health and ... equity investment in Marrodent, one of Poland,s ... $32 million. This transaction was announced on August 30, 2016. ... Poland since 2014, and Marrodent marks ...
(Date:12/8/2016)... Dec 8, 2016 Research and Markets has announced ... report to their offering. ... , The report provides separate comprehensive ... , and Rest of World. Annual estimates and ... historic analysis is provided for these markets. Market data and analytics are ...
(Date:12/7/2016)... Dec. 7, 2016 "Lantus (Insulin Glargine) Biosimilar Clinical Trial & ... biosimilar version of Lantus drug in clinical pipeline. Currently 5 biosimilar version ... Japan , Kenya , Czech ... , China , Slovakia , ... 2 diabetes mellitus. The patent on Lantus expired in 2014. Lantus ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... Coffey Agencies, a ... and commercial clients in the northern Alabama and Georgia regions, is embarking on ... 1977, Nobis Works has built a network of support and education facilities to ...
(Date:12/7/2016)... , ... December 07, 2016 , ... DrugDev ... announcement that it is one of the early adopters completing EU-U.S. Privacy Shield Certification ... designed to provide companies on both sides of the Atlantic with a mechanism to ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... ... celebrating the passage of the most comprehensive mental health systems reform legislation in ... support of the President, and the commitment of our elected officials to improving ...
(Date:12/7/2016)... York, NY (PRWEB) , ... December 07, 2016 ... ... amounts of the drug in their bodies, a researcher at the Icahn School ... journal Pediatric Research. , The study found that when young children are exposed ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... of Smart Device Remote Control through a new partnership with Splashtop Inc. This ... strengthens its mobile solutions to help businesses maximize their uptime and productivity. , ...
Breaking Medicine News(10 mins):